Gemini Therapeutics (GMTX) Competitors $58.97 -0.79 (-1.32%) As of 08/1/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsInsider TradesSEC FilingsTrendsBuy This Stock GMTX vs. VRNA, BBIO, BPMC, ROIV, LEGN, ELAN, RGC, RVMD, GRFS, and TGTXShould you be buying Gemini Therapeutics stock or one of its competitors? The main competitors of Gemini Therapeutics include Verona Pharma PLC American Depositary Share (VRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Regencell Bioscience (RGC), Revolution Medicines (RVMD), Grifols (GRFS), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Gemini Therapeutics vs. Its Competitors Verona Pharma PLC American Depositary Share BridgeBio Pharma Blueprint Medicines Roivant Sciences Legend Biotech Elanco Animal Health Regencell Bioscience Revolution Medicines Grifols TG Therapeutics Gemini Therapeutics (NASDAQ:GMTX) and Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Which has better valuation & earnings, GMTX or VRNA? Gemini Therapeutics has higher earnings, but lower revenue than Verona Pharma PLC American Depositary Share. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Verona Pharma PLC American Depositary Share, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-58.97Verona Pharma PLC American Depositary Share$42.28M211.78-$173.42M-$2.00-52.59 Which has more volatility and risk, GMTX or VRNA? Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Verona Pharma PLC American Depositary Share has a beta of 0.12, indicating that its share price is 88% less volatile than the S&P 500. Do analysts recommend GMTX or VRNA? Verona Pharma PLC American Depositary Share has a consensus price target of $109.00, suggesting a potential upside of 3.63%. Given Verona Pharma PLC American Depositary Share's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma PLC American Depositary Share is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Verona Pharma PLC American Depositary Share 0 Sell rating(s) 11 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.15 Does the media favor GMTX or VRNA? In the previous week, Verona Pharma PLC American Depositary Share had 11 more articles in the media than Gemini Therapeutics. MarketBeat recorded 11 mentions for Verona Pharma PLC American Depositary Share and 0 mentions for Gemini Therapeutics. Verona Pharma PLC American Depositary Share's average media sentiment score of 1.22 beat Gemini Therapeutics' score of 0.00 indicating that Verona Pharma PLC American Depositary Share is being referred to more favorably in the news media. Company Overall Sentiment Gemini Therapeutics Neutral Verona Pharma PLC American Depositary Share Positive Do insiders and institutionals have more ownership in GMTX or VRNA? 75.4% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 85.9% of Verona Pharma PLC American Depositary Share shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 4.8% of Verona Pharma PLC American Depositary Share shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is GMTX or VRNA more profitable? Gemini Therapeutics' return on equity of -38.78% beat Verona Pharma PLC American Depositary Share's return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Verona Pharma PLC American Depositary Share N/A -69.65%-28.00% SummaryVerona Pharma PLC American Depositary Share beats Gemini Therapeutics on 10 of the 14 factors compared between the two stocks. Get Gemini Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GMTX vs. The Competition Export to ExcelMetricGemini TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.56B$786.63M$5.53B$9.37BDividend YieldN/A4.84%4.74%4.12%P/E Ratio-58.971.3728.8823.79Price / SalesN/A25.69440.8796.30Price / CashN/A19.5635.0757.18Price / Book20.406.688.255.54Net Income-$71.87M-$3.67M$3.25B$259.88M7 Day Performance-2.71%-5.23%-3.75%-4.67%1 Month Performance15.33%-0.79%4.26%4.40%1 Year Performance36.28%15.44%25.83%17.91% Gemini Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GMTXGemini TherapeuticsN/A$58.97-1.3%N/A+38.5%$2.56BN/A-58.9730VRNAVerona Pharma PLC American Depositary Share2.1478 of 5 stars$104.90flat$109.00+3.9%+365.2%$8.93B$42.28M-52.4530Positive NewsUpcoming EarningsShort Interest ↑BBIOBridgeBio Pharma4.712 of 5 stars$45.90-1.3%$61.50+34.0%+80.9%$8.83B$221.90M-13.00400Upcoming EarningsAnalyst ForecastBPMCBlueprint Medicines0.7174 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsROIVRoivant Sciences2.0643 of 5 stars$11.48+0.3%$16.50+43.7%+6.5%$7.78B$29.05M-45.92860Upcoming EarningsLEGNLegend Biotech3.5599 of 5 stars$42.23+1.5%$73.33+73.7%-29.5%$7.64B$627.24M-71.582,609Positive NewsELANElanco Animal Health3.8108 of 5 stars$14.67-0.8%$16.00+9.1%+5.9%$7.34B$4.44B19.829,000Positive NewsUpcoming EarningsRGCRegencell Bioscience0.0457 of 5 stars$14.40-0.7%N/AN/A$7.17BN/A0.0010Positive NewsRVMDRevolution Medicines4.476 of 5 stars$38.42+0.3%$68.91+79.4%-19.1%$7.13B$11.58M-9.61250News CoveragePositive NewsUpcoming EarningsGRFSGrifols3.2348 of 5 stars$10.00+0.6%$10.30+3.0%+41.1%$6.83B$7.81B8.5523,822Dividend AnnouncementTGTXTG Therapeutics4.0678 of 5 stars$37.42-1.3%$43.80+17.0%+85.0%$6.02B$386.39M155.92290Positive NewsUpcoming Earnings Related Companies and Tools Related Companies Verona Pharma PLC American Depositary Share Alternatives BridgeBio Pharma Alternatives Blueprint Medicines Alternatives Roivant Sciences Alternatives Legend Biotech Alternatives Elanco Animal Health Alternatives Regencell Bioscience Alternatives Revolution Medicines Alternatives Grifols Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GMTX) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersI warned you about Nvidia… now look what’s happeningNvidia just got Trump’s greenlight to sell high-powered AI chips to China — and their stock surged 5% before t...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOne stock to replace NvidiaInvesting Legend Hints the End May be Near for These 3 Iconic Stocks One company to replace Amazon… another...InvestorPlace | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gemini Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
